Biotin-binding IgG (B-IgG) in human sera was quantified using previously developed F(ab) 2 anti-human IgG-coated multiwell microplates (Muratsugu M. et al., 2003, Biol. Pharm. Bull., 26, 1605-1608). The levels of B-IgG in sera, however, were higher than those we predicted. In this study, we modified the assay using F(ab) 2 anti-human IgG-coated multiwell microplates and successfully quantified the levels of B-IgG in sera. The cause of the unpredicted results was discussed in the text. In addition, the levels of biotin-binding IgA (B-IgA) and IgM (B-IgM) in sera could be measured using F(ab) 2 anti-human IgA-or IgM-coated multiwell microplates. We quantified B-IgG, B-IgA, and B-IgM in sera from healthy specimens and patients with bronchial asthma, atopic dermatitis, epilepsy, and juvenile rheumatoid arthritis.
Apart from these proteins, immunoglobulins to which biotin was covalently linked were found in human sera for the first time in 1993. 4) The prevalence of biotin-binding immunoglobulin was higher in patients with atopic dermatitis, other dermatitis, allergic disorders, and autoimmune disease. [4] [5] [6] Recently, biotin-binding IgG (B-IgG) was detected in a multiwell microplate format for the first time. 7) We developed a quantitative assay for B-IgG without any purification of samples using F(abЈ) 2 anti-human IgG-coated multiwell microplates. 8) We showed that the ratio of biotin to protein molecules (biotin-protein ratio) in B-IgG in human sera affected the detection limit in this assay 8) and how to determine the biotin-protein ratio of B-IgG as a standard for the B-IgG assay. 9) We investigated the sera of healthy specimens or patients using F(abЈ) 2 anti-human IgG-coated multiwell microplates. The levels of B-IgG in sera were higher than those we predicted.
In this study, we investigated the cause of the higher values of B-IgG in the sera used and modified the method using the F(abЈ) 2 anti-human IgG-coated multiwell microplates. We successfully applied the modified method to the measurement of biotin-binding IgA (B-IgA) and biotin-binding IgM (B-IgM) in sera.
MATERIALS AND METHODS

Materials
The following materials were obtained from the sources as indicated: flat-bottomed multiwell microplates (Immulon II) from Dynatech Laboratories, Inc., U.S.A.; 1,1,1-trichloro-2,2,2-trifluoroethane (TCTFE), from Tokyo Chemical Industry Co., Ltd., Tokyo, Japan; N-hydroxysuc- (PBS) . The amounts of standard biotinylated IgG (sB-IgG), IgA (sB-IgA), and IgM (sB-IgM) were expressed as the amounts of IgG, IgA, and IgM, respectively, which were determined using a BCA Protein Assay kit with human IgG as standard.
The biotin-protein ratio of each standard biotinylated protein was determined using the previous method 9) ; the ratios of sB-IgG, sB-IgA, and sB-IgM were 20, 23, and 100, respectively.
Quantitiation of Biotin-Binding Immunoglobulins Multiwell plates (96 wells) were coated with F(abЈ) 2 anti- human immunoglobulin by adding 100 ml of 75 mg ml Ϫ1 F(abЈ) 2 anti-human IgG, 76 mg ml Ϫ1 F(abЈ) 2 anti-human IgA, and 42 mg ml Ϫ1 F(abЈ) 2 anti-human IgM or 1% BSA (background) PBS plus 0.02% NaN 3 (PBS-N) to each well, then incubating overnight at 6°C. After the wells were washed 3 times with PBS-N, 300 ml of 1% BSA in PBS-N (PBS-NB) was added to each well. The plates were incubated for 2 h at 37°C and then washed 3 times with PBS-N. One hundred microliters of dilutions of standard biotinylated immunoglobulins or diluted test sera (serum : PBS-NBϭ1 : 9) was added to F(abЈ) 2 antibody or BSA-coated wells. After incubation for 2 h at 37°C, the plates were washed 3 times with PBS-N and then twice with PBS containing 0.05% merthiolate (PBS-M). One hundred microliters of avidin-biotinylated horse radish peroxidase complex (HRP-ABC), which was prepared according to the directions in the ABC kit with slight modifications before use, was added to each well. After 1 h of incubation, five washes in PBS-N and two washes in PBS-M, 100 ml of substrate solution in the CR kit was added to each well. After the plate was incubated at room temperature for a fixed time, the color reaction was terminated by the addition of the reactive stop solution in the kit to each well. Absorbance was measured at 490 nm in the microplate reader (Model 450, Bio-Rad Labs., Richmond, U.S.A.) and the data were transferred to a computer using a home-made program for data analysis. 10) Absorbances in F(abЈ) 2 anti-immunoglobulin-coated wells and BSA-coated wells were designated A F and A B , respectively, and DA was assigned to the difference between these absorbances (A F ϪA B ). This method is referred to as the F(abЈ) 2 ABC method in this study.
Trichlorotrifluoroethane-Treated Sera TCTFE was added to the serum (1 : 1 in volume), and then the mixture was vigorously agitated with the vortex mixer. After standing the mixture for 10 min, it was centrifuged at 900ϫg for 10 min. The level of B-IgG in the supernatant was measured with the F(abЈ) 2 ABC method.
Statistics Significance was examined using Fisher's exact probability test.
RESULTS AND DISCUSSION
Quantitation of B-IgG in Sera
We investigated the sera of healthy specimens or patients using the F(abЈ) 2 anti-human IgG-coated multiwell microplates developed previously, 8) and we found that the levels of B-IgG in sera were higher than those we predicted. Therefore, 100 ml of sera diluted with PBS-NB was added to F(abЈ) 2 anti-human IgG-coated wells and simultaneously to BSA-coated wells. The absorbance in each well was measured with the F(abЈ) 2 ABC method. The absorbances in F(abЈ) 2 anti-human IgG-coated wells were almost the same as those in BSA-coated wells for Serum No. 12, 27, 31, 36, 93, and 100 (Fig. 1A) . Since the absorbance in the BSA-coated wells meant that HRP-ABC nonspecifically adsorbed onto the well, these sera did not contain B-IgG. The absorbances in F(abЈ) 2 anti-human IgGcoated wells were higher than those in BSA-coated wells for Serum No. 17, 50, 51, 57, 63, and 88 (Fig. 1B) . The positive difference between absorbances in F(abЈ) 2 anti-human IgGcoated wells and those in BSA-coated wells (DAϾ0) meant that B-IgG existed in the sera (Serum No. 17, 50, 51, 57, 63, 88), because the absorbance obtained for BSA-coated wells implied the nonspecific binding of HRP-ABC.
One hundred microliters of 2.5, 5.0, or 10 ng ml Ϫ1 sB-IgG was added to F(abЈ) 2 anti-human IgG-coated wells and BSAcoated wells. The absorbance in each well was measured with the F(abЈ) 2 ABC method. The absorbances in F(abЈ) 2 anti-human IgG-coated wells elevated on increasing the concentration of sB-IgG added to each well (Fig. 2) . On the other hand, the absorbances in BSA-coated wells were lower than those in F(abЈ) 2 anti-human IgG-coated wells and did not depend on the concentration of sB-IgG (Fig. 2) . The results indicated that HRP-ABC did not adsorb onto the BSA-coated wells.
The higher absorbance in BSA-coated wells was observed when only sera were added to the wells, but not when sB-IgG solution was used. The result indicated that matter in sera nonspecifically adsorbed onto the F(abЈ) 2 anti-human IgG and/or BSA layers, and then HRP-ABC bound to the known/unknown substances in sera.
We treated the sera with TCTFE to investigate what caused the nonspecific adsorption of HRP-ABC.
Quantitation of B-IgG in the TrichlorotrifluoroethaneTreated Sera We examined the sera which showed the same absorbance in F(abЈ) 2 anti-human IgG-coated wells as that in BSA-coated wells (Group 1) or a higher absorbance in the former compared to the latter (Group 2). The supernatant consisting of the mixture of the serum and TCTFE was applied to the F(abЈ) 2 ABC method to measure the level of B-IgG, and the results was summarized in This result indicated that CTFE treatment removed matter from the serum. It is wellknown that treating a cloudy serum with TCTFE makes the serum clear, and milky serum contains many lipids like chylomicron. 11) Therefore, the nonspecific binding of lipids may cause a higher absorbance in BSA-coated wells; it seems that the lipids firstly adsorbed onto the BSA layer, and then HRP-ABC nonsepecifically adsorbed onto the lipids.
From these results, we thought that DA corresponded to the level of B-IgG in the serum.
Quantitation of B-IgG, B-IgA, and B-IgM in Sera BIgG could be measured between 0 and 10 ng ml
Ϫ1
, as previously reported. 8) Standard curves for B-IgA and B-IgM were linear from 0 to 20 ng ml Ϫ1 (data not shown). Diluted sera were added to both F(abЈ) 2 anti-human immunoglobulin-and BSA-coated wells, DA was calculated, and the levels of BIgG, B-IgA, and B-IgM were obtained using the standard curves.
B-IgG, B-IgA, and B-IgM in 100 sera from healthy specimens were analyzed using the F(abЈ) 2 ABC method ( Table  2 ). The reference value was defined as the meanϩ2S.D. and the values of B-IgG, B-IgA, and B-IgM were 1.42, 3.33, and 3.05 ng ml
, respectively. The ranges and positive percentages for B-IgG, B-IgA, and B-IgM are listed in Table 2 . Positive percentages for B-IgG were significantly increased in bronchial asthma (28.3%), atopic dermatitis (48.7%), epilepsy (52.9%), and juvenile rheumatoid arthritis (62.5%) as compared to healthy specimens (pϽ0.01). Positive percentages for B-IgA were significantly increased in bronchial asthma (13.2%) and atopic dermatitis (20.5%) as compared to healthy specimens (pϽ0.01). Biotin-binding immunoglobulin was first detected in the sera of epilepsy using the qualitative method. 4) Nagamine et al. 6) reported that the frequency of detection of biotin-binding immunoglobulin using the qualitative method was significantly higher in patients with bronchial asthma (25.0%), atopic dermatitis (43.8%), and rheumatoid arthritis (8.3%) than in healthy controls. The results for bronchial asthma and atopic dermatitis in this study were similar to their results. No significant correlations were found by regression analysis between B-IgG and B-IgA, B-IgG and BIgM, or B-IgA and B-IgM in bronchial asthma, atopic dermatitis, epilepsy, and juvenile rheumatoid arthritis (data not shown). The clinical significance of biotin-binding immunoglobulin is not clear at the present time, but the quantitative method we developed will be useful to elucidate the significance. CONCLUSION B-IgB, B-IgA, and B-IgM in human sera were successfully quantified using F(abЈ) 2 ABC method in which sB-IgB, sB- IgA, and sB-IgM with a confirmed biotin-protein ratio were used for the standard, respectively. When measuring biotinbinding immunoglobulins in human sera, we must use BSAcoated wells to avoid the nonspecific binding of HRP-ABC. Lipids like chylomicron in sera appeared to cause the nonspecific binding.
